Drawing for EE

USPTO serial 77783924

EE

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
SPARACINO, MARK V
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with EE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005medical diagnostic and therapeutic preparations for clinical use, all for administration via diverse routes of administration including through the respiratory airways, and, medical devices for administering the pharmaceuticals, sold as a kit, namely, inhalers; medical preparations, namely, nucleotides, proteins and organic molecules for medical use, including macromolecules such as anti-sense oligonucleotides and enzymes and small and inorganic molecules for treatment of human and non-human animal respiratory, central nervous system, neoplastic, endocrine, immune and cardiovascular ailments, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in some cases are adenosine receptor associated symptoms; pharmaceutical preparations for testing, and preventing and therapeutically treating respiratory, airway and pulmonary diseases and conditions, such as asthma, pulmonary vasconconstriction, inflammation, allergies, impeded respiration, acute respiratory disease syndrome (ARDS), renal damage and failure, ischemia resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating supra ventricular tachycardia (SVT), adenosine stress tests, infantile respiratory distress syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vasconcontriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemias, lymphomas, carcinomas, and the like, eg colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, etc, as well as metastatic cancers, eg, cancers which metastasized to the lung(s), breast, liver and prostateACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 21, 2011UNDNUNDELIVERABLE MAIL - NO ACTION TAKEN—
Oct 3, 2011MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 3, 2011ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 5, 2011WOAGWITHDRAWAL OF ATTORNEY GRANTED—
May 5, 2011WOARTEAS WITHDRAWAL OF ATTORNEY RECEIVED—
Mar 12, 2011EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 11, 2011EX2GSOU EXTENSION 2 GRANTED—
Mar 11, 2011AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Mar 1, 2011EXT2SOU EXTENSION 2 FILED—
Mar 1, 2011EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 2, 2010EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 31, 2010EX1GSOU EXTENSION 1 GRANTED—
Aug 31, 2010EXT1SOU EXTENSION 1 FILED—
Aug 31, 2010EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 2, 2010NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Dec 8, 2009NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 8, 2009PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 3, 2009PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Nov 3, 2009ALIEASSIGNED TO LIE—
Oct 19, 2009CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 19, 2009DOCKASSIGNED TO EXAMINER—
Jul 22, 2009MPMKNOTICE OF PSEUDO MARK MAILED—
Jul 21, 2009NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 21, 2009NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance